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Abstract
PX-478 is a new agent known to inhibit the hypoxia-
responsive transcription factor, HIF-1A, in experimental
tumors. The current study was undertaken in prepa-
ration for clinical trials to determine which noninvasive
imaging endpoint(s) is sensitive to this drug’s actions.
Dynamic contrast-enhanced (DCE) and diffusion-
weighted (DW) magnetic resonance imaging (MRI)
were used to monitor acute effects on tumor hemo-
dynamics and cellularity, respectively. Mice bearing
human xenografts were treated either with PX-478 or
vehicle, and imaged over time. DW imaging was per-
formed at three b values to generate apparent diffu-
sion coefficient of water (ADCw) maps. For DCE-MRI,
a macromolecular contrast reagent, BSA-Gd-DTPA,
was used to determine vascular permeability and vas-
cular volume fractions. PX-478 induced a dramatic
reduction in tumor blood vessel permeability within
2 hours after treatment, which returned to baseline by
48 hours. The anti-VEGF antibody, Avastin, reduced
both the permeability and vascular volume. PX-478 had
no effect on the perfusion behavior of a drug-resistant
tumor system, A-549. Tumor cellularity, estimated from
ADCw, was significantly decreased 24 and 36 hours
after treatment. This is the earliest significant response
of ADC to therapy yet reported. Based on these pre-
clinical findings, both of these imaging endpoints will
be included in the clinical trial of PX-478.
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Introduction
Solid tumors with areas of hypoxia are the most aggres-
sive and difficult tumors to treat [1]. Even micrometastases
have areas of hypoxia at the growing edge where tumor
growth outstrips new blood vessel formation [2,3]. Hypoxic
cancer cells survive the hostile hypoxic environment by chang-
ing to a glycolytic metabolism [4], becoming resistant to
programmed cell death (apoptosis) [5] and producing fac-
tors such as vascular endothelial growth factor (VEGF) that
stimulate new blood vessel formation from existing vascula-
ture (angiogenesis), leading to increased tumor oxygenation
and growth [6]. The cancer cell response to hypoxia is medi-
ated through the hypoxia-inducible factor-1 (HIF-1) transcrip-
tion factor [7,8]. HIF-1 is a heterodimer consisting of HIF1-a
and HIF-1b subunits, both members of the basic–helix– loop–
helix Per-ARNT-SIM (PAS) family of transcription factors [9].
HIF-1a and HIF-1b associate in the cytosol prior to transport to
the nucleus [10] where they bind to hypoxic regulated element
(HRE) DNA sequences in the 3V and 5V regions of hypoxia-
regulated genes [11]. HIF-1b is constitutively expressed and
its levels are not changed by hypoxia [7]. HIF-1a is constitu-
tively expressed but, under aerobic conditions, it is rapidly
degraded by the ubiquitin–26S proteasome pathway so that
HIF-1a levels are almost nondetectable [12]. Under condi-
tions of hypoxia, HIF-1a degradation is inhibited and HIF-1a
protein levels increase, resulting in an increase in HIF-1 trans-
activating activity.
HIF-1a expression has been detected in the majority of
solid tumors examined including brain, bladder, breast, colon,
ovarian, pancreatic, renal, and prostate tumors [13], whereas
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no expression was detected in surrounding normal tissues,
nor was it detected in benign tumors [14]. Clinically, HIF-1a
overexpression has been shown to be a marker of highly
aggressive diseases and has been associated with poor
prognosis and treatment failure in a number of cancers in-
cluding breast, ovarian, cervical, oligodendroglioma, esopha-
geal, and oropharyngeal cancers [15–19]. HIF-1a presence
correlates with tumor grade as well as vascularity [20,21].
High-grade glioblastoma multiforme has significantly higher
levels of VEGF expression and neovascularisation com-
pared with low-grade gliomas [22,23]. Studies such as these
suggest that HIF-1 mediates hypoxia-induced VEGF expres-
sion in tumors, leading to highly aggressive tumor growth.
PX-478 (S-2-amino-3-[4V-N,N,-bis(2-chloroethyl)amino]-
phenyl propionic acid N-oxide dihydrochloride) is a novel
agent that suppresses both constitutive and hypoxia-induced
levels of HIF-1a in cancer cells [24]. The inhibition of tumor
growth by PX-478 is positively associated with HIF-1a levels
in a variety of different human tumor xenografts in scidmice.
Magnetic resonance imaging (MRI) is a noninvasive
technique that can be used to obtain information regarding
tumor vascularization, metabolism, and pathophysiology, and
allows early assessment of therapeutic effects of cancer
drugs [25,26]. One approach is dynamic contrast-enhanced
(DCE) MRI, which measures tumor vascular characteris-
tics after administration of a contrast medium [27,28]. MRI
enhanced with small-molecular-weight contrast agents is
extensively used in the clinic to differentiate benign from
malignant lesions, as well as to monitor tumor microvascular
characteristics during treatment. However, the advantage
of using large molecular agents (macromolecular contrast
media, or MMCM) designed for prolonged intravascular
retention has been demonstrated in several preclinical stud-
ies [29–32]. Correlations betweenMMCM-enhancedparame-
ters and angiogenic markers such as microvessel density and
VEGF levels have been studied [33,34]. Diffusion-weighted
(DW) MRI allows noninvasive characterization of biologic
tissues based on the random microscopic motion of water
proton measurement, referred to as the apparent diffusion
coefficient of water (ADCw) [35]. Preclinical studies have
shown that DWI allows early detection of tumor response to
chemotherapy [36–41]. Most likely, changes in the diffusion
characteristics are caused by a shift of water to the extra-
cellular space [42]. It is therefore anticipated that DW-MRI
will detect early changes in cellular volume fractions resulting
from apoptosis-associated cell shrinkage, necrosis, or vaso-
genic edema [43,44]. Because water is not as diffusionally
restricted in the extracellular space, compared to the intra-
cellular space, a decrease in cell volume fraction will result
in an overall increase in the ADCw. We have previously
characterized the capability of DWI to detect early changes
in tumor ADCw following antitumor therapy in preclinical
models [45,46] and in the clinical setting [47].
This study monitored the antitumor activity of PX-478,
an HIF-1a inhibitor soon to enter clinical testing, on HT-29
human colon xenografts using both DCE and DW-MRI and
assessed the use of these techniques as early and surrogate
endpoints for the antitumor response to the drug. These
noninvasive magnetic resonance techniques provide in-
sights on tumor microvessel characteristics, such as PSP
and vascular volume fraction, and on cellular volume ratios
(cellularity and necrotic fraction), which may be early markers
and even predictors of tumor response.
Materials and Methods
Cell Line and Tumor Implantation
HT-29, a tumorigenic nonmetastatic human colon carci-
noma cell line, and A-549, a non small cell human lung
cancer cell line, were obtained from the American Tissue
Type Collection (Rockville, MD). Cells were passaged twice
weekly with a 1:2 split and cultured in Dulbecco’s modified
Eagle’s medium (DMEM:F12) supplemented with 10% fetal
bovine serum (HyClone, Fort Collins, CO). For inoculation,
approximately 106 cells in 0.1 ml of media were injected
subcutaneously into the right flank of female severe com-
bined immunodeficient (SCID) mice of ages 5 to 6 weeks
(Arizona Cancer Center Experimental Mouse Shared Ser-
vices, Tucson, AZ). Mice developed palpable tumors within a
week of inoculation. Tumors were allowed to grow to 100 to
500 mm3 prior to imaging. All animal protocols were ap-
proved by the University of Arizona Institutional Animal Care
and Use Committee (IACUC; Tuczon, AZ).
Treatments
PX-478 was provided by Prolx Pharmaceuticals (Tucson,
AZ) and prepared fresh each day in 0.9%NaCl as a 10mg/ml
solution and administered intraperitoneally to the mice
within 30 minutes of preparation. Mice were treated with
either vehicle or 125 mg/kg PX-478, and were studied 2,
12, 24, or 48 hours later. A minimum of eight animals were
examined with MRI at each time point (four to six controls,
and four to six treated). An additional 36-hour time point
was included in the DW-MRI protocol. For imaging, mice
were anesthesized using 1.0% to 2.0% isoflurane carried
in oxygen. Body temperature was maintained at 37jC
with a circulating water blanket and was monitored using
a rectal Luxtron fluoroptic thermometer (Luxtron, Santa
Clara, CA). Contrast agent, Gd-DTPA, coupled to albumin
(Gd-BSA, 0.6 mg/g in 0.15 ml of saline), was injected by
a tail vein catheter comprising a 30-gauge needle connected
to PE-20 polyethylene tubing. The Gd-BSA was synthesized
by the Arizona Cancer Center Synthetic Chemistry Core
(Tucson, AZ). Chemical analysis indicated that there were
an average of 3.8 Gd bound per protein molecule. The
human anti-VEGF antibody Avastin (bevacizumab; Genen-
tech, San Francisco, CA) was administered intravenously at
a dose of 20 ml/30 g.
MRI
All imagings were performed on a 4.7-T horizontal
bore MR imager (Bruker, Billerica, MA). Mice were posi-
tioned into a 24-mm ID Litzcage coil (Doty Scientific, Colum-
bia, SC). Sagittal scout images were obtained to determine
the position of tumors.
476 Monitoring Therapy Response with MRI Jordan et al.
Neoplasia . Vol. 7, No. 5, 2005
DW-MRI methodology. Contiguous axial 2.0-mm slices
covering the entire tumor were imaged as per the follow-
ing protocol. DW images were obtained using the DIFRAD
sequence [48], with the acquisition parameters: TR = 2 sec-
onds, TE = 36 milliseconds, D = 13 milliseconds, d = 5 milli-
seconds, matrix size = 128  128, and FOV = 4  4 cm,
where d and D represent the duration and separation of dif-
fusion gradients, respectively. At each slice location, images
were obtained at three b values (25, 500, and 950 sec/mm2),
with a time resolution of 13 minutes for a complete data set.
The b value is equal to c2Gd
2d2(D(d/3)), where Gd is the
strength of the diffusion weighting gradient and c is the
gyromagnetic ratio for protons. Images were reconstructed
using a filtered backprojection algorithm of magnitude data
to minimize motion artifacts. ADCw maps were generated
by fitting the three b values to the Stejskal-Tanner equa-
tion, S = S0e
bADCw, where S0 is the signal intensity in the
absence of diffusion weighting and S is the signal intensity
with diffusion weighting. ADCw maps were analyzed using
programs written in Interactive Data Language (Research
Systems, Boulder, CO). Hand-drawn regions of interest
(ROIs) corresponding to tumor localized on the scout scans
were cloned onto the ADCw maps, and ADCw distribution
histograms were obtained for each tumor. For each time
point (2, 12, 24, 36, and 48 hours after vehicle or PX-478
injection), two groups (one control and one treated) of four
to six mice were imaged. In addition, four mice were moni-
tored over the full time course, independently of the DCE-
MRI protocol, to confirm the pattern observed on separate
groups of mice.
DCE-MRI acquisition and analysis. Contiguous axial 2.0-mm
slices covering the entire tumor as well as a slice over the
kidneys were imaged in the following protocol. A proton
density–weighted (TR = 8 seconds, TE = 5.9 milliseconds,
NA = 2, and FOV = 4  4 cm) and a T1-weighted spin-echo
image (TR = 300milliseconds, TE = 5.9 milliseconds, NA = 8,
and FOV = 4  4 cm) were collected prior to injection of con-
trast. A dynamic series of spin-echo images (TR = 300 milli-
seconds, TE = 5.9 milliseconds, NA = 4, FOV = 4 4 cm, and
NR = 19) were collected over 45 minutes, with the contrast
agent solution being injected during repetitions 2 to 5.
Signal enhancement in the DCE data was converted
to albumin–Gd-DTPA concentration using the relaxivity of
1.08 l/g s measured in vitro at 37jC. This can be converted to
64.8 mM albumin/sec, assuming a MW of 60 kDa. Enhance-
ment was converted to concentration by assuming a linear
relationship between Gd concentration and relaxation rate
enhancement. These [albumin–Gd-DTPA] versus time data
were fitted to a straight line for each pixel to obtain a slope
(related to vascular permeability times the vascular surface
area, PSP) and y-axis intercept (related to the vascular
volume). In the absence of vascular volume changes, the
PSP is referred to simply as ‘‘permeability.’’
The vascular volume (VV) parameter measured in tumor
pixels was normalized to the mean value obtained in an ROI
placed on a muscle in the same animal and multiplied
by 5% (fVV fraction of the muscle) to convert it to the
vascular volume fraction of the tumor. To be able to compare
values between different mice, the slope parameter was
normalized for Gd dose as follows for each mouse. The
mean slope parameter calculated from pixels falling within
the vena cava was used to normalize the slope determined
in the tumor. The vena cava was identified using a hand-
drawn ROI of approximately 5 to 10 pixels. Data analysis
was performed using programs written in Interactive Data
Language (Research Systems).
Antitumor Studies
The doses of PX-478 used for antitumor studies were
80 mg/kg daily for 5 days for the HT-29 colon cancer
xenograft mice and 100 mg/kg daily for 5 days for the
A-549 lung cancer xenograft mice. There were eight mice
in each group. Tumor volume was measured twice weekly
until the tumor reached 2000 mm3, or became necrotic,
at which point the animals were euthanized. Orthogonal
tumor diameters (dshort and dlong) were measured twice
weekly with electronic calipers and converted to volume
by the formula: volume = (dshort)
2(dlong)/2. Log10 cell kill was
calculated by the formula: log10 cell kill = (tumor growth
delay [day]) / (tumor doubling time [day]  3.32). One-way
analysis of variance using the general linear model was
used to test for the effect of treatment on tumor growth rate
and growth delay.
HIF-1a Immunohistochemistry
Paraffin-embedded tumor sections were heated at
60jC for 30 minutes and rehydrated through xylene and
graded alcohols. Antigen retrieval was at 40 minutes at pH
9.0 for HIF-1a. The slides were blocked for 30 minutes in
4% milk, 1% goat serum, and 0.1% thimerosal in phosphate-
buffered saline (PBS). After blocking, the slides were
processed using a Ventana Medical Systems ES autoslide
stainer. Endogenous peroxidase activity was quenched
using a hydrogen peroxide–based inhibitor (DAB Basic
Detection Kit; Ventana Medical Systems, Tucson, AZ)
and endogenous biotin blocked using an AB Blocking Kit
(Ventana Medical Systems). The slides were incubated
for 32 minutes at 42jC with the mouse monoclonal
antihuman HIF-1a (Transduction Laboratories, Lexington,
KY) at 10 g/ml. A biotinylated universal secondary antibody,
which recognized mouse IgG/IgM, was applied, followed
by horseradish peroxidase–conjugated avidin, DAB/
hydrogen peroxide, and a copper enhancer. The slides
were dehydrated through graded alcohols, toluene and
xylene, and coverslipped using Vectamount (Vector Labo-
ratories, Burlingame, CA). HIF-1a staining was normalized
to the staining of an onslide control of hypoxic HT-29 colon
cancer cells.
VEGF Detection
Plasma was collected into EDTA tubes and tumors
were removed and immediately snap-frozen in liquid nitro-
gen. Tumors were then placed in buffer (10 mM Tris/HCl,
pH 7.4, and 100 mM NaCl) and homogenized using
a PowerGen 125 (Fisher Scientific, Pittsburg, PA). The
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suspension was then centrifuged twice at 8000g at 4jC
for 15 minutes. Protein was quantitated in a supernatant
using the Pierce (Rockford, IL) BCA assay. VEGF levels
were quantitated in plasma and tumor lysates using both
human (hVEGF) and mouse VEGF (mVEGF) ELISA (R&D
Systems, Minneapolis, MN), according to the manufac-
turer’s instructions.
Statistical Analysis
Data are presented as the mean and standard error of
the mean (SEM). Two-tailed Student’s t tests, ANOVA, or
Mann–Whitney rank sum tests were used where appropriate.
P < .05 was considered to be statistically significant.
Results
Effect of PX-478 on HT-29 Tumor ADCw
DW-MRI was used to detect the early response of HT-29
tumor xenografts to the antitumor agent, PX-478. A single
gradient direction was used in this study because previous
studies have shown the absence of anisotropy in extracra-
nial tumor models [46,49]. ADC maps from representative
animals at different times posttherapy are shown in Figure 1.
Changes in mean tumor ADCw values over time, posttreat-
ment, are presented in Figure 2. No change in ADC distri-
bution was observed in sham-treated animals (Figure 2).
At early time points (2 and 12 hours), ADCw values were
not significantly different between control and treated
groups. A substantial increase in mean relative tumor ADCw
was observed for the treated groups at 24 and 36 hours
posttreatment (94.5 ± 4.8%, P = .005, and 38.4 ± 4.9%,
P = .01, respectively) before returning to pretreatment mean
ADCw values by 48 hours posttreatment (nonsignificant
change of 2.5% ± 6.7%, P = .38). ROIs defining the tumor
were used to generate histograms of tumor ADCw values.
ADCw histograms of individual tumors were then summed
for each time point (Figure 2). A right shift in tumor water
diffusion beginning by 24 hours after therapy is shown in
Figure 2. Water diffusibility was still increased by 36 hours
posttreatment and appeared to return to pretreatment values
by the second day after therapy. This significant change in
ADC (by 24 hours) occurs sooner than in other reports.
Effects of PX-478 on HT-29 Tumor DCE-MRI Parameters
Extravasation of the Gd-BSA was assumed to be describ-
able by a PSP-limited two-compartment model with uni-
directional transport of contrast agent on the timescale of
our DCE-MRI experiments.
Parameter maps of ‘‘permeability’’ and vascular volume
fraction were created to visualize the heterogeneity of tumor
hemodynamic parameters. Heterogeneities in the distribu-
tions of pharmacokinetic parameters have previously been
shown in experimental as well as in human tumors. Typical
permeability (P ) and vascular volume fraction (VV) maps
at each time point are shown in Figure 3. Tumors were iden-
tified on proton density–weighted images and delineated
by hand-drawn ROIs. Tumor vascular PSP is dramatically
decreased in the PX-478 group 2, 12, and 24 hours after
treatment in comparison with the control group (Figure 3A).
Figure 1. DW images at a b value of 25 (up) and corresponding diffusion maps (bottom) of an HT-29 tumor-bearing mouse before, 24 hours, and 48 hours after
PX-478 injection. Each image represents an axial slice of the mouse with the tumor area encircled and indicated by an arrow.
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This decrease is no longer observed by 48 hours after
treatment. Although some individual changes (positive or
negative) in tumor vascular volume fraction were sometimes
observed (Figure 3B; 2 and 24 hours posttreatment), the
mean change between groups was not statistically signifi-
cant. Hence, we conclude that the mechanism underlying the
change in PSP is due to alterations in permeability, with little
or no change in surface area, because surface area changes
will also be reflected in the vascular volume estimation.
Time courses of mean normalized values and mean
VV fraction values are presented in Figure 4 (relative
data) and Table 1 (normalized values). A rapid decrease
in tumor blood vessel permeability was observed within
2 hours after drug administration compared to control
tumors, with a mean reduction of 73.3 ± 13.9% (P = .012).
The decrease in permeability was still 72.4 ± 6.9% at
12 hours after treatment (P = .003). The effect progressively
decreased in later time points, with a mean reduction of
55.0 ±10.3% (P = .02) at 24 hours posttreatment and a
return to control values at 48 hours (3.9 ± 10.9 %, P = .71,
not significant). By contrast, the vascular volume fraction
of the tumor was not significantly modified at any time
point and remained unchanged between control and
treated tumors.
Histogram analyses of these data lose spatial informa-
tion yet retain the distribution of values for quantitative
analyses. Figure 5 shows histogram data summed for all
animals in each group. Control tumors at each time point
(filled bars in each plot) were characterized by hetero-
geneous and broad distributions of ‘‘permeability’’ values
at all time points. In contrast, treated tumors showed more
homogeneous and narrow histograms centered around
much lower values at 2, 12, and 24 hours (open bars).
Note that the range of median of the distribution of perme-
ability values returned to control levels at 48 hours. These
data can also be further reduced to median values (dashed
vertical lines in each population), which were significantly
decreased in the treated groups 2, 12, and 24 hours
after treatment.
Effects of Anti-VEGF Antibodies on HT-29 Tumor
DCE Parameters
To assess the ability of the MMCM DCE technique to
detect acute changes after treatment with an antitumor
agent aimed at decreasing VEGF in this tumor model, human
anti-VEGF antibody (Avastin) was administered to HT-29
tumor-bearing mice. A 75.0 ± 4.0 % decrease in vascular
PSP was observed within an hour of injection of the anti-
body (P < .0001), similar to the changes observed 2 and
12 hours after PX-478 administration (Figure 6A, Table 1).
The anti-VEGF antibody treatment also induced a signifi-
cant 31.5 ± 2.6 % (P = .023) decrease in vascular volume
fraction, unlike treatment with PX-478 (Figure 6A, Table 1).
Hence, in this case, the PSP changes may not be entirely
due to permeability, and may also involve alterations in the
vascular surface area.
Figure 2. Top: Full time course of average tumor ADCw following PX-478 administration (control mice, full line; treated mice, dotted line). A significant increase in
average tumor ADCw is observed at 24 and 36 hours posttreatment. Bottom: Summed ADCw histograms of control (filled bars) and treated tumors (open bars) at
each time point. A right shift in tumor ADCw is observed at 24 and 48 hours posttreatment.
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Effects of PX-478 on A-549 Tumor DCE Parameters
A-549 non small cell lung tumors are resistant to PX-
478 (Antitumor Studies section and Ref. [24]) and were
therefore used as negative controls for the DCE-MRI proto-
col. No significant change was observed for either tumor
permeability or vascular volume fraction (Figure 6B, Table 1).
These data suggest that the changes observed on HT-29
xenografts after administration of PX-478 are connected to
the sensitivity of this tumor model to the drug. Notably, the
untreated PSP values of A-549 tumors were lower than the
control values obtained in HT-29 tumors, suggesting that
baseline PSP values may be prognostic for the antitumor
effects of PX-478, although further investigation is required.
Antitumor Effect of PX-478 on HT-29 and A-549 Xenografts,
HIF-1a Staining, and VEGF Detection
HT-29 colon cancer xenografts exhibited staining for
HIF-1a, whereas A-549 non small cell lung cancer xeno-
grafts showed very little staining (Figure 7). The A-549 lung
cancer xenografts showed no growth inhibition when treated
with PX-478 (100 mg/kg, i.p.) daily for 5 days, whereas the
HT-29 colon cancer xenografts exhibited a tumor growth
delay of 16 days with a calculated log cell kill of 1.6 (P < .05).
The lack of responsiveness to PX-478 by A-549 tumors is
probably due to the lack of HIF-1a expression in these
tumors compared to HT-29 xenografts (Figure 7). The lower
permeability observed is probably explained by the lower
expression of VEGF-A, an HIF-1 target gene. Levels of
VEGF-A are also markedly lowered in A-549 tumors versus
HT-29 tumors (50.12 ± 12.09 vs 1.81 ± 0.23 pg/mg, P = .012,
Mann–Whitney rank sum test) as measured by ELISA.
Discussion
The activity of PX-478, an inhibitor of HIF-1a in experimental
tumors, was evaluated on HT-29 human colon xenografts
using both DCE and DW-MRI. PX-478 induced a substantial
reduction in tumor blood vessel permeability as early as
2 hours after a single dose of 125 mg/kg, which persisted
until 24 hours posttreatment, and had returned to control
values by 48 hours. The tumor vascular volume fraction
was not significantly altered over the same time course.
Although the time course of response was different for
diffusion MRI, tumor ADCw was also shown to be an early
marker of tumor response. No change in tumor ADCw could
be observed at very early time points, but a significant in-
crease was shown 24 and 36 hours after treatment, having
returned to control values by 48 hours posttreatment.
Tumor vessel permeability to MMCM has been used
in the preclinical setting to assess the efficacy of differ-
ent antiangiogenic therapies [27,30,32,34,50]. MMCM-
enhanced MRI has been demonstrated to be capable of
monitoring the direct antivascular effects of anti-VEGF anti-
body treatment in xenografts [51–53]. Changes in tumor
vascular parameters have been measured by DCE-MRI
using clinically approved small molecule contrast agents in
Figure 3. (A) Permeability maps of tumors 2, 12, 24, and 48 hours after either vehicle (control) or drug (PX-478) injection. Each image represents an axial slice
of the mouse with the tumor area encircled. A substantial reduction in tumor vascular permeability is observed as soon as 2 hours after PX-478 injection and until
24 hours, in comparison with the control situation. This is no longer observed by 48 hours after treatment. (B) Vascular volume fraction (VV) maps of tumors 2, 12,
24, and 48 hours after either vehicle (control) or drug (PX-478) injection. Each image represents an axial slice of the mouse with the tumor area encircled. Some
individual positive or negative changes can be observed, but these were not significant between groups.
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animal human tumor xenograft models following treatment
with the small molecule VEGF receptor tyrosine kinase
inhibitors ZD6474 [54] and PTK787/ZK222584 [55,56], and
anti-VEGF antibody [57–59]. DCE-MRI studies in patients
with colon cancer receiving PTK 787/ZK222584 as part of
Phase I trials, while showing heterogeneity in tumor vascular
response, have shown a significant correlation between
tumor perfusion and the dose of PTK 787/ZK222584, with
patients with stable disease having a significantly greater
reduction in the transfer constant, K
trans
, which is related to
flow, permeability, and vascular surface area [55]. Patients
receiving anti-VEGF antibody as part of Phase I trial have
also exhibited a reduction in tumor K
trans
measured by DCE-
MRI after the first treatment [60]. In the present study, we
observed acute changes within an hour following anti-
VEGF antibody therapy using the large molecular contrast
agent, Gd-BSA. This suggests that the reductions in vas-
cular permeability parameters measured by DCE-MRI were
related to changes in tumor VEGF levels. In this context, PX-
478 has been shown to decrease both HIF-1a and VEGF
staining in HT-29 tumors [24]. However, the time course for
the decrease in HIF-1a and VEGF was different from the
changes in PSP measured by DCE-MRI. In our previous
study, both HIF-1a and VEGF decreased within 2 hours
and returned to control values by 8 hours after treatment.
In contrast, in the current study, the vascular permeability
estimated from MMCM kinetics was still reduced 24 hours
after treatment. Also, Avastin led to changes in both vas-
cular volume and PSP, whereas PX-478 affected only PSP,
which is interpreted to be due to permeability changes alone.
The differences between these responses are unknown,
but may also indicate that the effect of PX-478 on hemo-
dynamics is not mediated through VEGF. However, it also
remains possible that the hemodynamics is affected by
localconcentrations or threshold values of VEGF, and these
cannot yet be measured. In patients, increased VEGF ex-
pression has been correlated with the progression of colon
carcinoma [61] and with the development of colon cancer
metastasis [62]. In node-negative primary colon cancer,
elevated tumor VEGF has been correlated with decreased
patient survival [63]. Also, increased tumor VEGF expres-
sion has been associated with increased tumor angiogenesis
and metastasis of human gastric cancer [64]. However, the
estimation of VEGF levels is now more controversial as an
accurate marker of therapeutic efficacy. Clinical studies
focused on the relation between angiogenic markers (micro-
vascular density or VEGF levels), and quantitative DCE-MRI
enhancement data have shown mixed results [33,34].
Su et al. [33] concluded that the lack of correlation could
be partly due to the inability of DCE-MRI with low-molecular-
weight agents to reveal the true vascular function within
the tumor. Bhujwalla et al. [34] recently described the
Figure 4. Full time course of average vascular permeability (A) and vascular
volume fraction (B) following administration of PX-478 (control mice, full line;
treated mice, dotted line). Blood vessel permeability was estimated from the
slope of the enhancement curves, and tumor vascular volume (VV) fraction
was estimated from the ordinate. A significant reduction in permeability is
observed 2, 12, and 24 hours after treatment with PX-478, whereas no
changes are observed in the VV fraction.
Table 1. Absolute Values of DCE-MRI Enhancement Parameters after Treatment with PX-478 or Avastin.
Tumor Model Tx 1 hr Post-Tx 2 hr Post-Tx 12 hr Post-Tx 24 hr Post-Tx 48 hr Post-Tx
nP (104) VVf (%) nP (104) VVf (%) nP (104) VVf (%) nP (104) VVf (%) nP (104) VVf (%)
HT-29 Control 0.65 ± 0.04 6.4 ± 0.7 0.62 ± 0.07 6.5 ± 1.2 0.62 ± 0.06 6.0 ± 0.5 0.62 ± 0.01 6.0 ± 0.8 0.60 ± 0.01 5.8 ± 0.9
PX-478 n.d. 0.17 ± 0.09* 7.5 ± 1.8 0.17 ± 0.04** 5.7 ± 0.3 0.28 ± 0.06* 6.6 ± 0.8 0.62 ± 0.05 6.6 ± 0.7
Avastin 0.16 ± 0.03** 4.4 ± 0.2* n.d.
A-549 Control n.d. 0.35 ± 0.01 6.3 ± 0.4 n.d.
PX-478 0.34 ± 0.01 6.0 ± 0.7
Normalized permeability (nP) and vascular volume fraction (VVf) values (mean ± SEM) for control (carrier injection), PX-478 (125 mg/kg, i.p.), and Avastin (20 l/
30 g, i.v.) groups. Note that the permeability is significantly decreased 2, 12, and 24 hours after treatment with PX-478 and within 1 hour after treatment with the
anti-VEGF antibody Avastin, and that the VVf is only affected by Avastin.
*P < .05 relative to the control group (t-tests).
**P < .01 relative to the control group (t-tests).
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antiangiogenic effect of the fumagillin derivative, TNP-470,
by MMCM DCE-MRI. They observed a heterogeneous re-
sponse, with some regions of decreased PSP and some
regions with increased PSP values resulting in an apparent
lack of overall response, based on the average value of
tumor PSP, whereas ELISA assays detected an increase
of tumor VEGF. DCE-MRI was shown to be a more reliable
marker by taking into account tumor heterogeneity. Our
results suggest that DCE-MRI might be a more sensitive
measure of functional tumor permeability, or that perme-
ability factors other than VEGF might be involved in the
response to PX-478.
Importantly, a lack of change in the PSP of A-549 tumors
between control and treated tumors was observed in this
study. This correlates well with the inability of PX-478 to
induce growth delays in A-549 tumors. In this case, the lack
of an effect may be due to the lower baseline PSP values
in A-549 compared to HT-29 tumors. It also implies that the
effect of this drug on vascular parameters is mediated
through the tumor cells themselves and not the host vascu-
lature, which was the same in both tumor settings.
It has been suggested in the past that DCE-MRI could be
used to monitor clinical response to anti-VEGF and inhibition
of angiogenesis [54–57,65]. The current findings suggest
that DCE-MRI may also be useful to assess the response to
inhibition of HIF-1. However, it should be acknowledged that
the current study used MMCM, which are currently unavail-
able in a clinical setting. These results emphasize the need
to develop MMCM for monitoring antivascular therapies. Our
finding that a tumor with low HIF-1a staining, which was not
responsive to anti–HIF-1 therapy, also had a very low vas-
cular PSP as measured by MMCM DCE-MRI suggests that
DCE-MRI may also be useful clinically for screening and
preselecting patients for therapy with anti–HIF-1 and other
antiangiogenic therapies.
DW-MRI is able to detect early changes in the morpho-
logy and physiology of tissues after antineoplastic therapies.
An increase in tumor ADCw could result from changes in cell
membrane permeability, cell shrinkage, or vasogenic edema.
Vasogenic edema results from high vessel permeability that
results in the movement of osmotically active proteins and
associated water to the interstitium. This mechanism is
unlikely to be the cause of increased ADC in the current
system because vessel permeability decreased in response
to PX-478. Both of these are associated with cell death and
result in the modification of the intracellular to extracellular
water populations ratio [43]. Parameters such as cell density
and necrotic fraction have indeed been monitored with
diffusion MRI [49,66]. In this study, we observed an increase
in tumor ADCw that is consistent with other studies using
other tumors and drugs [37–41,44,46,67]. In these studies,
Figure 5. Summed permeability histograms of control (open, n = 4) and treated tumors (plain, n = 4) at each time point. Note that the median (dotted line) of the
treated tumors is lower than the median value of the controls. It is progressively shifted to the median of the controls over time, and is back at control values
48 hours posttreatment.
Figure 6. (A) Relative change in HT-29 tumor vascular permeability and
vascular volume fraction 1 hour after treatment with anti-VEGF antibody
(Avastin). A significant reduction in permeability as well as in VV fraction is
observed with this positive control. (B) Relative change in A-549 tumor
(resistant to the antitumor activity of PX-478, negative control) vascular
permeability, and vascular volume fraction 2 hours after treatment with
PX-478. No significant change is observed in DCE parameters.
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an increase in ADCw is correlated with ultimate tumor re-
sponse, whether by apoptosis or other means of cell death.
Notably, the current data document the earliest significant
increase in chemotherapy-induced ADCw. Previous reports
have indicated that the earliest significance was not reached
until 48 hours following therapy [36,39].
The combination of dynamic and DWMRI in the follow-up
of chemotherapy has been used in the past [68,69] and has
been proven to be of good predictive value for therapy
outcome in patients with primary rectal carcinoma [70]. In
this study, the acquisition of both DW and DCE images in a
single protocol on the same animal allowed us to coregister
these data and compare the two techniques. We define the
dynamic range (DR) as the maximum change relative to the
variance of controls. For these studies, the DR was higher
for DW-MRI (maximum effect at 24 hours, DR = 8.7) than
for DCE-MRI (maximum effect at 2 hours, DR = 3.2). Tumor
ADCw was thereby shown to be a sensitive and early marker
of tumor response in this study. Nonetheless, the DCE-MRI
response preceded the diffusion response and opened up
the possibility of monitoring acute effects of drug in vivo. The
combination of the two techniques gives unique insights
into the complex response of HT-29 tumors to PX-478 by
showing very early changes in vascular permeability fol-
lowed by large changes in cellularity. Considering the mag-
nitude of response of HT-29 xenografts to PX-478 observed
with early and sensitive markers, we can speculate that
noninvasive monitoring of PX-478 by DCE and/or diffusion
MRI will be of particular interest in the clinic.
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